RenovoRx Inc (RenovoRx) is a medical device company. The company develops solutions for targeted delivery of diagnostic, therapeutic agents and chemotherapeutic drugs targeting peripheral vascular system. Its proprietary Trans-Arterial Micro-Perfusion (TAMP), technology platform provides chemotherapy for the treatment of solid tumors in the peripheral system. RenovoRx lead product RenovoCath, a medical device system with dual-balloon infusion catheter that delivers intra-arterial chemotherapy directly to the tumor. It also investigating TIGeR-PaC, a systemic chemotherapy for pancreatic cancer. RenovoRx is headquartered in Los Altos, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company RenovoRx Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
RenovoRx Inc Company Overview
RenovoRx Inc Company Snapshot
RenovoRx Inc Pipeline Products and Ongoing Clinical Trials Overview
RenovoRx Inc – Pipeline Analysis Overview
RenovoRx Inc - Key Facts
RenovoRx Inc - Major Products and Services
RenovoRx Inc Pipeline Products by Development Stage
RenovoRx Inc Ongoing Clinical Trials by Trial Status
RenovoRx Inc Pipeline Products Overview
RenovoCath System - Bile Duct Cancer
RenovoCath System - Bile Duct Cancer Product Overview
RenovoCath System - Pancreatic Cancer
RenovoCath System - Pancreatic Cancer Product Overview
RenovoCath System - Pancreatic Cancer Clinical Trial
Mar 12, 2024: RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
Dec 19, 2023: RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
Dec 13, 2023: RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
Nov 16, 2023: RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.
Jul 31, 2023: RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference
Apr 17, 2023: RenovoRx presenting phase III clinical trial interim analysis data of the TIGeR-PaC study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida
Jan 18, 2023: RenovoRx announces initial results in pharmacokinetic (PK) substudy: Data on RenovoGem supports potential for RenovoTAMP therapy platform to increase local Gemcitabine (chemotherapy) delivery and decrease side effects of pancreatic cancer treatment
Jan 05, 2023: RenovoRx strengthens Intellectual Property (IP) portfolio with eighth US Patent
Dec 15, 2022: RenovoRx announces acceptance of four clinical data abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) Symposium
Table 10: RenovoCath System - Bile Duct Cancer - Product Status
Table 11: RenovoCath System - Bile Duct Cancer - Product Description
Table 12: RenovoCath System - Pancreatic Cancer - Product Status
Table 13: RenovoCath System - Pancreatic Cancer - Product Description
Table 14: RenovoCath System - Pancreatic Cancer - Targeted Intra-arterial Gemcitabine Versus Continuation of IV Gemcitabine Plus Nab-paclitaxel Following Induction with Sequential IV Gemcitabine Plus Nab-paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
Table 15: Retractable Coil - Interventional Oncology - Product Status